相关实验视频

Updated: Jun 24, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

揭示有效抑制HDAC8的关键结构特征:使用定量读横结构-活性关系 (q-RASAR) 和药模拟的综合性研究

Samima Khatun¹, Indrasis Dasgupta¹, Rakibul Islam²

¹Laboratory of Drug Design and Discovery, Department of Pharmaceutical Technology, Jadavpur University, Kolkata, 700032, India.

Molecular diversity

|June 13, 2024

概括

这项研究开发了一个使用q-RASAR和药模拟的计算框架,以确定选择性HDAC8抑制的关键结构特征,为改进的疗法铺平道路.

科学领域:

药用化学医学化学
计算生物学计算生物学
酶抑制可以抑制酶.

背景情况:

基因组脱乙酶 (HDACs) 是生物过程中至关重要的酶.
抑制HDAC8是各种疾病的治疗策略.
目前的HDAC8抑制剂缺乏选择性,需要开发向药物.

研究的目的:

为了确定强效和选择性HDAC8抑制的关键结构特征.
为合理的药物设计建立一个计算框架.
引导开发新的HDAC8向治疗方法.

主要方法:

定量结构-活动关系 (QSAR) 和定量阅读-跨结构-活动关系 (q-RASAR) 建模.
药测绘,分子对接和分子动力学 (MD) 模拟.
对描述器贡献和关键交互特征 (HBA,RA,ZBG) 的分析.

主要成果:

开发了一个高度预测性的q-RASAR模型 (Q ² _F1:0.778,Q ² _F2:0.775).
最好的药理模型显示了高精度 (R:0.969,RMSD:0.944),强调了HBA,RA和ZBG特征.
分子对接和MD模拟验证了这些结构特征对HDAC8相互作用的重要性.

结论:

这项研究完善了对抑制HDAC8的基本结构要求的理解.
为设计选择性HDAC8抑制剂提供了一个强大的计算框架.
这些发现为药物化学家和药物开发研究人员提供了宝贵的见解.

关键词:

描述器描述器是一个描述器.在 HDAC8 中,HDAC8 是模拟MD的模拟方法分子对接是分子对接.药科类动物 (Pharmacophore) 是一种药科类动物.在QSAR中使用QSAR.

更多相关视频

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...